Prior notification of a concentration (Case M.11512 – OTPP / NORDIC CAPITAL / ADVANZ PHARMA) – Candidate case for simplified procedure
Date: 2024-06-11
Institutions: Directorate-General for Competition, European Commission
Subjects: economic concentration, investment company, merger control, pension scheme, pharmaceutical product, supply, teacher








C_202403694EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2024/3694


11.6.2024






Prior notification of a concentration
(Case M.11512 – OTPP / NORDIC CAPITAL / ADVANZ PHARMA)
Candidate case for simplified procedure
(Text with EEA relevance)
(C/2024/3694)


1.   
On 31 May 2024, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:






—


Ontario Teachers’ Pension Plan Board (‘OTPP’, Canada),










—


Nordic Capital XI, L.P. (‘Nordic Capital XI’, Channel Islands) an affiliate of the Nordic Capital group of funds and vehicles (‘Nordic Capital’) (Channel Islands).




OTPP and Nordic Capital will acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of the Advanz Pharma group of companies, (‘Advanz Pharma’, Channel Islands), currently solely controlled by Nordic Capital.
The concentration is accomplished by way of purchase of shares.


2.   
The business activities of the undertakings concerned are the following:






—


OTPP is a corporation without share capital incorporated under the Teachers’ Pension Act in Ontario, Canada. OTPP is concerned with the global administering of pension benefits and global investment of pension plan assets on behalf of active and retired teachers in Ontario, Canada,










—


Nordic Capital XI is an affiliate of Nordic Capital, a private equity firm which through its funds invests in large and medium sized companies.






3.   

The business activities of Advanz Pharma are in the supply of pharmaceutical products.



4.   
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
Pursuant to the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004 on the control of concentrations between undertakings (2) it should be noted that this case is a candidate for simplified treatment under the procedure set out in the Notice.


5.   
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.11512 – OTPP / NORDIC CAPITAL / ADVANZ PHARMA
Observations can be sent to the Commission by email or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu

Postal address:





European Commission




Directorate-General for Competition




Merger Registry




1049 Bruxelles/Brussel




BELGIQUE/BELGIË







(1)  
            OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2)  
            OJ C 160, 5.5.2023, p. 1.


ELI: http://data.europa.eu/eli/C/2024/3694/oj
ISSN 1977-091X (electronic edition)